ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Oppenheimer

Oppenheimer began coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report released on Thursday. The brokerage issued an outperform rating and a $9.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on PRQR. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

ProQR Therapeutics Stock Down 5.0%

NASDAQ:PRQR opened at $1.72 on Thursday. The business’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.07. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $3.10. The company has a market cap of $180.96 million, a PE ratio of -3.66 and a beta of 0.21.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently made changes to their positions in PRQR. Osaic Holdings Inc. boosted its position in ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new stake in ProQR Therapeutics in the fourth quarter worth $35,000. Moody Lynn & Lieberson LLC acquired a new stake in ProQR Therapeutics in the fourth quarter worth $50,000. Invesco Ltd. bought a new stake in ProQR Therapeutics in the fourth quarter valued at $51,000. Finally, Fifth Third Bancorp bought a new stake in ProQR Therapeutics in the third quarter valued at $64,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.